- Home
- NVNO
as 07-26-2024 4:00pm EST
enVVeno Medical Corp is a medical device company focused on the development of bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. Its product, the VenoValve, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).
| Founded: | 1987 | Country: | United States |
| Employees: | N/A | City: | IRVINE |
| Market Cap: | 66.8M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 50.3K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.40 - $6.97 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest enVVeno Medical Corporation News
NVNO Breaking Stock News: Dive into NVNO Ticker-Specific Updates for Smart Investing
ACCESSWIRE
a month ago
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
ACCESSWIRE
a month ago
Positive Interim Venous Ulcer Healing Data Showing Significant Improvement from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented Today at the Society for Vascular Surgery 2024 Vascular Annual Meeting
ACCESSWIRE
a month ago
New Interim Venous Ulcer Healing Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the Society for Vascular Surgery 2024 Vascular Annual Meeting on June 21, 2024
ACCESSWIRE
3 months ago
enVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate Update
ACCESSWIRE
3 months ago
Positive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross Symposium
ACCESSWIRE
3 months ago
New Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024
ACCESSWIRE
4 months ago
enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer
ACCESSWIRE
4 months ago
enVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno Opportunity
Compare NVNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVNO enVVeno Medical Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.